<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620178</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-CSE-ATA-2008/1</org_study_id>
    <nct_id>NCT00620178</nct_id>
  </id_info>
  <brief_title>Atacand (Candesartan) Real Life Study</brief_title>
  <acronym>Real Life</acronym>
  <official_title>A REtrospective Study on the Effects of cAndesartan vs. Losartan on Blood Pressure, Health Care Consumption and cardiovascuLar Events In a &quot;Real-liFe&quot; GP sEtting in Sweden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This study is a Swedish historical cohort study in patients prescribed Atacand or Cozaar for
      hypertension by selected primary care centres. Data will be extracted anonymously from
      electronic medical records. In addition, data regarding morbidity and mortality will be
      collected by merging the cohort with the following national registries: the Hospital
      Discharge Register (Slutenvårdsregistret), the Cause of Death Register and the Heart
      Intensive Care Admission (RIKS-HIA)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy objective is to investigate, on basis of 'first to event', the development of new cardiovascular diseases (CVD).</measure>
    <time_frame>1999 - 2007</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular disease states and procedures in the background and over the entire observation period will be identified by use of ICD-9 and ICD-10 coding for diseases of the cardiovascular system. Specifically are death, acute cardiovascular events, new</measure>
    <time_frame>1999 - 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care consumption will be assessed as contacts with health care providers, in-hospital time periods for cardiovascular disease states with associated therapeutic procedures, and times spent within various levels of care (e.g. ICU and general ward).</measure>
    <time_frame>1999 - 2007</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">14000</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Candesartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Losartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Cilexetil</intervention_name>
    <description>oral once daily dose</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ATACAND</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>once daily oral dose</description>
    <arm_group_label>2</arm_group_label>
    <other_name>COZAAR</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible subjects are all patients found in EPS systems at the participating centres, who
        were prescribed candesartan (ATC-C09CA06) or losartan (C09CA01) for hypertension from 1
        January 1999 - 31 December 2004 inclusive. The first found prescription is designated as
        index.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recorded blood pressure prior to therapy of &gt; 140 and/or 90 mmHg

          -  Diagnosed as hypertensive within 15 months

          -  First prescription of Cozaar or Atacand between 1 January 1999 and 31 December 2007,
             inclusive

        Exclusion Criteria:

          -  Previous prescription within 15 months any drug from the ATC groups C02, C03, C07 -
             C09 inclusive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Stålhammar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eriksbergs vårdcentral</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2008</study_first_submitted>
  <study_first_submitted_qc>February 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <last_update_submitted>December 1, 2010</last_update_submitted>
  <last_update_submitted_qc>December 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Anders Ljunggren, MD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>candesartan</keyword>
  <keyword>losartan</keyword>
  <keyword>blood pressure</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>health care consumption</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

